Tumor tissue collected by re-biopsy was analyzed by next generation sequencing with an OncoAim Lung cancer targeting gene detection kit (Singlera Genomics, Inc., Shanghai, China) and revealed an acquired ERBB2 amplification (ERBB2_amp) in conjunction with EGFR 19 deletion mutation. The gene discussed is EGFR; the disease is neoplasm.